College of Medicine, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL, United States of America.
Department of General and Colorectal Surgery, Poznan University of Medical Sciences, Poznan, Poland.
PLoS One. 2019 Aug 30;14(8):e0222013. doi: 10.1371/journal.pone.0222013. eCollection 2019.
Colorectal cancer is recognized as the fourth leading cause of cancer-related deaths worldwide. Thus, there is ongoing search for potential new biomarkers allowing quicker and less invasive detection of the disease and prediction of the treatment outcome. Therefore, the aim of our study was to identify colorectal cancer specific miRNAs expressed in cancerous and healthy tissue from the same patient and to further correlate the presence of the same miRNAs in the circulation as potential biomarkers for diagnosis. In the current study we detected a set of 40 miRNAs differentially regulated in tumor tissue when comparing with healthy tissue. Additionally, we found 8 miRNAs differentially regulated in serum of colorectal cancer patients. Interestingly, there was no overlap in miRNAs regulated in tissue and serum, suggesting that serum regulated miRNAs may be not actively secreted from colorectal tumor cells. However, four of differentially expressed miRNAs, including miR-21, miR-17, miR-20a and miR-32 represent the miRNAs characteristic for different tumor types, including breast, colon, lung, pancreas, prostate and stomach cancer. This finding suggests important groups of miRNAs which can be further validated as markers for diagnosis of tumor tissue and regulation of carcinogenesis.
结直肠癌被认为是全球癌症相关死亡的第四大主要原因。因此，人们一直在寻找潜在的新生物标志物，以实现更快、更微创的疾病检测和治疗效果预测。因此，我们的研究目的是鉴定来自同一患者的癌组织和正常组织中特异性表达的结直肠癌细胞 miRNA，并进一步在循环系统中存在相同的 miRNA 作为潜在的诊断生物标志物。在本研究中，我们在肿瘤组织与正常组织比较时检测到了一组 40 个差异调节的 miRNA。此外，我们还发现了 8 个在结直肠癌患者血清中差异调节的 miRNA。有趣的是，组织和血清中调节的 miRNA 之间没有重叠，这表明血清调节的 miRNA 可能不是从结直肠肿瘤细胞中主动分泌的。然而，四个差异表达的 miRNA，包括 miR-21、miR-17、miR-20a 和 miR-32，代表了不同肿瘤类型的 miRNA，包括乳腺癌、结肠癌、肺癌、胰腺癌、前列腺癌和胃癌。这一发现表明了一些重要的 miRNA 可以作为肿瘤组织诊断和致癌作用调控的标志物进一步验证。
